Project Grant S10OD040170
- Federal Grant Award Summary Vanderbilt University has been awarded $558,651 through the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) for a five-year Project Grant beginning August 1, 2025 and concluding July 31, 2030. The award supports research on the discovery and engineering of ribosomally synthesized and post-translationally modified peptides (RIPPs), with focus on advancing genomics, enzymology, and structure-function...
- Federal Project Grant Award Summary Vanderbilt University received a $4.0 million Project Grant award dated July 15, 2025, from the National Science Foundation's Office of Integrative Activities under the Integrative Activities program (CFDA 47.083). The award will support the development of a next-generation Matrix-Assisted Laser Desorption/Ionization (MALDI) Trapped Ion Mobility Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometry platform for high-performance molecular...
- Federal Project Grant Award Summary Vanderbilt University received a $1,281,400 project grant awarded May 15, 2026, under the Research Infrastructure Programs (CFDA 93.351) funded by the National Institutes of Health (NIH) Office of the Director. The award supports the acquisition and installation of a LUMICKS C-Trap DYMO300 microscope system to be housed within the Vanderbilt Center on Mechanobiology. This advanced instrument combines optical tweezers technology for exerting molecular and...
- Federal Project Grant Award Summary The National Science Foundation (NSF) Office of Advanced Cyberinfrastructure awarded Vanderbilt University $248,968 under the Computer and Information Science and Engineering (CFDA 47.070) program to develop high-throughput computational workflows for elucidating the origin of lasso peptide handedness. The project, led by Professor Zhongyue John Yang in the Department of Chemistry, runs from September 1, 2025, through August 31, 2028. The research deliverables...
- Federal Grant Award Summary Vanderbilt University received a $435,875 Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective June 1, 2026 through January 31, 2031. This award funds fundamental research to elucidate the structural mechanisms of calcium signaling at endoplasmic reticulum-mitochondria contact sites (EMCs), with particular focus on inositol 1,4,5-trisphosphate receptors (IP3Rs) and...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $421,632 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective August 15, 2025, through April 30, 2029. The award supports research to develop a novel platform for generating partially synthetic Chemical Exchange Saturation Transfer (CEST) Magnetic...
- Federal Grant Award Summary Vanderbilt University received a $1.2M project grant awarded September 1, 2025, from the National Science Foundation's Division of Computer and Network Systems under the Computer and Information Science and Engineering (CISE) program (CFDA 47.070). The project, titled "Intelligent Cyber Microscopy System for Long-Term Microscope Imaging" (ICMS), will develop an AI-powered cyber-physical system that transforms biological microscopy capabilities through the...
- Federal Grant Award Summary Vanderbilt University received a $489,644 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for July 31, 2027. The project aims to develop novel drug-coated balloon (DCB) therapies using peptide-based delivery mechanisms to improve long-term vessel patency following angioplasty in peripheral arterial disease (PAD) treatment....
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded Indiana University Indianapolis a five-year Project Grant totaling $383,880 under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026 through February 28, 2031. The award supports research to develop novel synthetic and chemical biology approaches for expanding the chemical diversity of phage display libraries, a screening technology used to identify therapeutic...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $700,000 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded August 8, 2025, with completion by July 31, 2028. This award supports the development of novel radiosynthesis methods using direct [11C]CO2 methylation for production of carbon-11...
Federal Grant Award Summary Vanderbilt University received a $128,860 Project Grant from the National Institutes of Health Office of the Director under the Research Infrastructure Programs (CFDA 93.351) on May 15, 2026, to acquire a Liberty Blue 2.0 Solid-Phase Peptide Synthesizer manufactured by CEM Corporation. The instrument enables the institution to conduct in-house synthesis of customized peptides incorporating non-proteinogenic amino acids, macrocyclizations, and site-specific chemical modifications—capabilities previously unavailable at Vanderbilt and therefore requiring costly external vendor procurement with extended lead times. The synthesizer will directly support ongoing NIH-funded research initiatives across 15 departments in the College of Arts and Science, the School of Medicine Basic Sciences, the Vanderbilt Institute of Chemical Biology, and Vanderbilt University Medical Center. The instrument serves a broad user base conducting research applications ranging from fluorophore-labeled peptides for receptor trafficking studies to cleavable linkers for antibody-drug conjugates targeting methicillin-resistant Staphylococcus aureus, macrocyclic peptides for cystic fibrosis therapeutics, and structure- and artificial intelligence-guided molecular design requiring rapid synthesis of candidate compounds. The one-year project period runs through May 14, 2027, with the equipment installation and operational setup supporting timely, affordable access to high-quality customized peptides essential to contemporary biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $128.9k | 5/26/26 |